Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Age and exercise effect on metabolomics in rats (Study ST000759)

C18 NEGATIVE ION MODE (Analysis AN001196)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8	F9	F10
FFA(22:0)	ME211119	0.53	0.45	0.49	0.48	0.51	6.20	0.60	0.59	0.44	0.46
FFA(24:1)	ME211123	0.50	0.36	0.37	0.59	0.25	6.57	0.73	0.75	0.38	0.30
PE 37:5; [M-H]-@6.20	ME211168	0.94	0.52	0.68	0.81	0.70	4.48	0.50	0.51	0.74	0.67
PI 38:5; [M-H]-@5.37	ME211186	0.76	0.92	0.88	0.62	0.86	4.14	0.51	0.55	0.66	0.66
FFA(18:0)	ME211113	0.70	0.67	0.67	0.66	0.72	4.09	0.76	0.75	0.67	0.73
FFA(22:1)	ME211120	0.71	0.62	0.63	0.75	0.57	3.90	0.77	1.02	0.74	0.65
PI 40:5; [M-H]-@5.96	ME211189	0.62	0.76	0.71	0.61	1.00	3.54	0.53	0.72	1.01	0.79
PI 40:6; [M-H]-@5.80	ME211190	0.47	0.63	0.78	0.59	1.07	3.71	0.34	0.56	1.25	0.84
lysoPE 22:6; [M-H]-@1.28	ME211196	0.77	0.95	0.79	0.79	0.56	3.89	0.25	0.47	0.77	1.13
lysoPE 22:5; [M-H]-@1.54	ME211195	1.00	1.13	0.68	0.54	0.57	3.43	0.56	0.63	0.77	1.00
lysoPE 16:0; [M-H]-@1.64	ME211193	0.87	0.86	0.64	0.71	0.58	3.53	0.70	0.87	0.68	0.88
lysoPE 18:0; [M-H]-@2.40	ME211194	0.88	0.86	0.66	0.74	0.60	3.44	0.60	0.71	0.79	1.01
PC 42:9; [M-Ac-H]-@5.97	ME211160	0.58	0.75	0.87	1.06	0.72	3.37	0.69	0.71	0.90	0.70
PI 36:1; [M-H]-@6.32	ME211180	1.05	0.87	0.69	1.25	0.70	3.06	0.72	0.73	0.81	0.55
PI 34:1; [M-H]-@5.68	ME211178	0.83	1.20	0.80	0.52	1.00	3.14	0.65	0.77	0.96	0.53
FFA(16:0)	ME211112	0.80	0.84	0.83	0.80	0.75	2.92	0.83	0.79	0.80	0.88
PC 39:5; [M-Ac-H]-@6.67	ME211153	0.80	1.18	0.87	0.85	0.69	2.85	0.68	0.69	0.87	0.82
FFA(18:1)	ME211114	0.93	1.47	1.08	1.26	0.50	2.67	0.59	0.42	0.72	0.83
FFA(18:2)	ME211115	0.96	1.42	1.09	1.25	0.48	2.72	0.60	0.45	0.74	0.78
FFA(20:2)	ME211118	0.80	1.20	0.93	1.12	0.45	2.32	0.68	0.72	0.95	1.00
PC 38:3; [M-Ac-H]-@7.11	ME211149	1.12	0.83	0.92	1.10	0.66	2.42	0.83	0.73	0.96	0.71
PC 33:1; [M-Ac-H]-@6.44	ME211132	0.86	1.00	0.76	1.18	0.62	1.85	0.94	1.11	0.91	0.87
PC 35:1; [M-Ac-H]-@7.04	ME211138	0.81	0.82	0.68	1.08	0.60	1.80	0.75	1.31	0.99	1.09
PC 40:3; [M-Ac-H]-@7.58	ME211154	0.90	0.86	0.86	0.75	0.70	1.55	0.82	1.07	1.36	0.98
plasmenyl-PE 42:6; [M-H]-@7.75	ME211212	0.69	0.88	0.67	0.90	0.69	1.79	0.64	0.88	1.43	1.22
Arachidonic acid	ME211103	0.73	0.91	0.75	0.91	0.57	2.00	1.06	0.81	1.19	1.00
plasmenyl-PE 38:2; [M-H]-@7.88	ME211204	0.78	0.90	0.64	1.13	0.36	1.68	0.91	0.95	1.55	0.90
PE 38:3; [M-H]-@7.22	ME211171	0.83	0.78	1.11	0.81	0.91	2.17	0.66	0.76	1.23	0.85
PE 35:2; [M-H]-@6.69	ME211163	0.78	0.98	1.29	0.92	0.78	1.80	0.78	1.13	0.79	0.93
PE 37:4; [M-H]-@6.69	ME211167	0.89	0.56	1.25	0.90	0.72	1.95	0.85	0.87	0.89	1.17
FFA(24:0)	ME211122	0.85	0.79	0.70	0.82	0.63	2.04	1.51	1.23	0.73	0.76
FFA(24:2)	ME211124	0.45	0.60	0.49	0.66	0.44	2.52	1.02	1.44	1.12	1.06
PC 36:5; [M-Ac-H]-@5.69	ME211143	1.44	1.33	1.38	1.32	0.84	1.74	0.60	0.75	0.61	0.58
PC 39:4; [M-Ac-H]-@7.11	ME211152	1.09	1.26	1.00	1.16	0.79	1.92	0.74	0.79	0.70	0.87
PC 40:7; [M-Ac-H]-@6.22	ME211157	0.86	1.35	1.12	1.18	0.92	1.80	0.59	0.70	0.84	0.94
plasmenyl-PE 32:0; [M-H]-@7.06	ME211197	1.23	1.20	1.98	1.20	0.86	1.38	0.61	0.51	0.86	0.65
CL 74:7; [M-2H](2-)@6.09	ME211107	1.16	1.02	1.40	0.97	0.56	1.63	0.65	0.87	1.00	0.90
PE 36:1; [M-H]-@7.42	ME211165	1.09	0.82	1.65	1.09	0.98	1.52	0.54	0.93	0.90	0.77
CL 70:1; [M-2H](2-)@6.81	ME211104	1.26	0.87	1.52	1.01	0.80	1.23	0.84	0.94	0.89	0.83
PE 34:1; [M-H]-@6.84	ME211162	1.28	0.94	1.67	1.03	0.73	1.27	0.79	0.93	0.94	0.68
PE 38:2; [M-H]-@6.88	ME211170	1.51	1.24	1.18	1.58	0.56	0.55	1.03	0.88	0.77	0.90
CL 74:1; [M-2H](2-)@6.72	ME211105	1.25	1.09	1.14	1.38	0.51	0.41	1.05	1.06	0.81	1.25
PC 35:2; [M-Ac-H]-@6.55	ME211139	1.26	1.26	0.96	1.25	0.47	0.54	1.26	1.08	0.82	1.06
CL 74:5; [M-2H](2-)@6.53	ME211106	1.46	1.22	1.65	1.62	0.51	0.74	0.68	0.96	0.68	0.83
PE 40:5; [M-H]-@7.07	ME211175	1.19	1.13	1.51	1.41	0.57	0.71	0.60	0.71	1.18	1.04
PA 34:2; [M-H]-@6.25	ME211125	0.70	1.50	0.64	1.23	0.72	1.29	0.99	0.95	0.75	1.24
PE 37:2; [M-H]-@6.61	ME211166	1.13	1.52	0.80	0.84	0.27	0.79	1.29	0.88	0.86	1.43
PC 30:1; [M-Ac-H]-@5.42	ME211127	1.47	0.89	1.13	1.24	0.34	0.99	0.45	1.04	1.23	1.15
CL 82:13; [M-2H](2-)@6.41	ME211110	1.10	1.17	1.27	1.00	0.70	1.14	0.26	1.45	0.92	1.07
CL 78:11; [M-2H](2-)@6.01	ME211108	0.93	0.99	1.70	0.91	0.81	0.87	0.41	1.05	1.03	1.28
PE 38:6; [M-H]-@6.25	ME211172	0.88	1.08	1.61	0.86	0.78	0.95	0.47	1.06	1.11	1.17
plasmenyl-PE 40:6; [M-H]-@7.22	ME211211	0.96	0.92	0.74	1.09	0.80	0.85	0.74	0.88	1.55	1.19
plasmenyl-PE 38:6; [M-H]-@6.57	ME211208	0.93	1.17	0.64	0.87	0.76	0.80	0.85	1.01	1.39	1.28
plasmenyl-PE 40:4; [M-H]-@7.74	ME211209	1.04	0.90	0.65	0.73	0.59	0.80	0.92	1.32	1.44	1.22
plasmenyl-PE 38:4; [M-H]-@7.32	ME211206	0.87	0.99	0.68	0.93	0.66	0.80	1.05	1.21	1.39	1.11
plasmenyl-PE 38:5; [M-H]-@6.74	ME211207	0.98	1.03	0.64	0.86	0.60	0.77	0.97	1.16	1.50	1.15
plasmenyl-PE 40:5; [M-H]-@7.31	ME211210	0.98	0.95	0.66	0.88	0.67	0.73	0.95	1.24	1.56	1.03
FFA(22:2)	ME211121	0.80	0.85	0.86	1.06	0.48	1.12	1.19	1.24	1.05	1.15
plasmenyl-PE 38:3; [M-H]-@7.44	ME211205	0.81	0.77	0.61	0.82	0.67	0.67	1.24	1.42	1.51	1.03
PC 33:2; [M-Ac-H]-@5.97	ME211133	0.81	0.89	0.78	0.78	0.56	0.80	1.27	1.59	1.12	1.09
plasmenyl-PE 36:3; [M-H]-@6.88	ME211203	0.66	0.90	0.96	0.83	0.67	0.84	1.14	1.29	1.27	1.12
PG 36:2; [M-H]-@6.09	ME211177	1.10	1.15	1.29	0.93	1.17	1.38	0.58	0.70	1.14	0.79
plasmenyl-PE 34:1; [M-H]-@7.16	ME211199	0.93	1.13	1.52	1.10	0.86	1.11	0.71	0.58	1.22	0.94
PI 38:6; [M-H]-@5.12	ME211187	1.28	0.98	1.26	0.95	0.87	1.08	0.46	0.78	1.19	1.16
PC 38:4; [M-Ac-H]-@6.77	ME211150	1.11	1.12	1.07	1.12	1.08	0.89	0.76	0.78	1.08	1.04
PE 40:4; [M-H]-@6.86	ME211174	1.09	1.13	1.11	1.05	1.04	1.05	0.73	0.81	1.09	0.99
CerP 42:2; [M-H]-@7.71	ME211111	1.16	1.26	0.99	1.21	0.92	1.07	0.76	0.91	1.03	0.83
PC 38:5; [M-Ac-H]-@6.40	ME211151	1.28	1.40	1.19	1.14	1.00	0.99	0.70	0.76	0.91	0.87
plasmenyl-PE 34:2; [M-H]-@6.74	ME211200	0.84	1.02	1.29	1.08	0.74	0.71	1.02	0.95	1.31	0.93
plasmenyl-PE 36:1; [M-H]-@7.70	ME211201	1.00	0.91	1.06	1.05	0.73	0.99	0.95	1.24	1.27	0.74
PC 37:3; [M-Ac-H]-@6.74	ME211145	1.02	1.16	1.26	0.92	0.86	1.14	0.87	1.08	0.90	0.90
plasmenyl-PE 36:2; [M-H]-@7.33	ME211202	1.09	1.07	1.23	1.05	0.72	1.02	1.01	1.07	1.05	0.77
PC 32:2; [M-Ac-H]-@5.63	ME211131	1.05	1.15	0.96	0.87	0.63	0.62	0.98	1.11	1.16	1.24
PC 32:0; [M-Ac-H]-@6.61	ME211129	1.01	1.08	0.88	0.85	0.72	0.95	0.86	1.07	1.25	1.14
PC 36:4; [M-Ac-H]-@6.22	ME211142	1.02	1.16	0.93	1.02	0.90	0.79	0.89	0.95	1.16	1.09
PC 34:3; [M-Ac-H]-@5.80	ME211136	1.10	1.29	1.12	1.28	0.76	0.81	0.78	0.96	0.91	1.07
PC 38:1; [M-Ac-H]-@7.86	ME211147	0.93	1.22	1.03	1.15	0.70	1.09	0.79	1.00	1.01	1.09
PE 38:1; [M-H]-@7.34	ME211169	1.07	1.16	1.02	1.19	0.76	0.94	0.83	0.89	1.01	1.13
PC 38:2; [M-Ac-H]-@7.45	ME211148	1.00	1.04	0.94	0.93	0.69	1.24	0.98	1.19	1.06	0.91
CL 78:5; [M-2H](2-)@6.42	ME211109	1.02	1.15	0.89	1.03	0.65	0.96	0.97	1.14	1.04	1.07
PC 34:1; [M-Ac-H]-@6.67	ME211134	1.11	1.05	0.90	1.14	0.67	1.04	0.93	1.04	1.06	1.02
PC 34:2; [M-Ac-H]-@6.22	ME211135	1.22	1.18	0.93	1.04	0.77	0.68	1.06	1.18	0.97	0.95
PC 36:2; [M-Ac-H]-@6.85	ME211141	1.34	1.17	1.01	1.10	0.80	0.82	0.99	1.11	0.91	0.84
FFA(20:1)	ME211117	0.96	1.20	0.97	1.26	0.61	0.62	1.09	1.26	1.06	0.90
PC 31:0; [M-Ac-H]-@6.24	ME211128	1.11	1.27	0.94	1.28	0.57	0.63	0.89	1.30	0.91	1.06
PG 36:0; [M-H]-@6.88	ME211176	1.26	0.96	1.04	1.11	0.95	0.69	0.99	0.83	1.05	1.09
PE 36:0; [M-H]-@7.85	ME211164	1.22	1.20	1.29	1.27	0.72	0.71	0.96	0.88	0.92	0.94
PC 32:1; [M-Ac-H]-@6.10	ME211130	1.41	1.27	1.03	1.21	0.68	0.67	0.78	1.06	0.92	1.03
PC 42:4; [M-Ac-H]-@8.03	ME211158	1.39	1.29	1.04	1.19	0.56	0.68	0.80	0.78	1.18	1.08
PC 40:4; [M-Ac-H]-@7.35	ME211155	0.79	1.26	0.79	0.93	0.82	1.73	0.70	0.88	1.02	1.11
PI 34:2; [M-H]-@5.24	ME211179	1.10	0.91	0.95	0.74	1.08	1.63	0.76	0.87	1.09	0.95
PI 36:2; [M-H]-@5.88	ME211181	1.05	1.13	0.84	0.73	0.93	1.71	0.77	0.92	1.07	0.93
PI 36:3; [M-H]-@5.42	ME211182	1.03	1.16	0.87	0.70	0.96	1.82	0.86	0.88	1.06	0.79
PC 37:4; [M-Ac-H]-@6.54	ME211146	0.89	0.95	1.05	0.80	0.95	1.16	0.79	1.04	1.18	1.09
PI 38:3; [M-H]-@6.08	ME211184	0.94	1.04	0.93	0.97	1.03	1.33	0.89	0.97	1.05	0.90
PI 36:4; [M-H]-@5.23	ME211183	1.08	1.05	0.88	0.72	1.17	1.31	0.88	0.89	1.05	1.01
PI 38:4; [M-H]-@5.85	ME211185	1.06	1.10	0.81	0.81	1.19	1.11	0.86	0.89	1.10	1.05
PC 40:5; [M-Ac-H]-@7.01	ME211156	0.97	1.05	0.92	1.07	1.13	1.29	0.66	0.69	1.22	1.04
PC 42:6; [M-Ac-H]-@7.36	ME211159	0.90	1.12	0.91	1.13	0.85	1.56	0.50	0.70	1.17	1.18
PC 36:0; [M-Ac-H]-@7.82	ME211140	1.24	1.22	0.95	1.29	1.25	1.25	0.81	0.88	0.72	0.73
PC 37:2; [M-Ac-H]-@7.16	ME211144	1.25	1.21	0.98	1.12	0.74	1.53	0.86	1.03	0.71	0.83
FFA(20:0)	ME211116	1.06	0.93	1.04	1.17	0.72	1.24	1.13	0.99	0.80	1.00
PE 40:3; [M-H]-@7.12	ME211173	1.39	1.00	0.91	1.02	0.91	1.28	1.08	0.90	0.80	0.88
PI 39:4; [M-H]-@6.13	ME211188	1.24	1.40	0.81	0.56	1.04	1.72	1.11	1.28	0.51	0.67
PC 35:0; [M-Ac-H]-@7.47	ME211137	1.21	1.45	0.83	1.14	0.65	0.96	0.86	2.12	0.31	0.71
PA 36:3; [M-H]-@6.23	ME211126	1.22	1.13	0.85	1.13	0.72	0.67	1.47	1.50	0.56	0.82
PE 34:0; [M-H]-@6.62	ME211161	0.96	1.16	0.94	0.91	0.53	0.99	0.96	1.89	0.72	0.90
plasmenyl-PE 34:0; [M-H]-@7.20	ME211198	0.86	0.92	1.01	0.89	0.74	1.02	1.17	1.72	0.86	0.76
PS 38:4; [M-H]-@6.00	ME211191	0.41	1.48	0.82	0.51	0.84	0.63	0.83	1.16	1.64	1.23
PS 38:5; [M-H]-@5.46	ME211192	0.45	0.79	0.48	0.85	0.35	0.62	0.76	2.15	1.90	0.98

Factors:

F1	Age:106 week \| Line:HRT \| Sex:Female \| Training:no
F2	Age:106 week \| Line:HRT \| Sex:Female \| Training:yes
F3	Age:106 week \| Line:LRT \| Sex:Female \| Training:no
F4	Age:106 week \| Line:LRT \| Sex:Female \| Training:yes
F5	Age:126 week \| Line:HCR \| Sex:Male \| Training:no
F6	Age:126 week \| Line:LCR \| Sex:Male \| Training:no
F7	Age:14 week \| Line:HCR \| Sex:Male \| Training:no
F8	Age:14 week \| Line:LCR \| Sex:Male \| Training:no
F9	Age:4 week \| Line:HCR \| Sex:Male \| Training:no
F10	Age:4 week \| Line:LCR \| Sex:Male \| Training:no

Data matrix